Modern Vaccines Adjuvants & Delivery Systems

12-14 September 2017, Crowne Plaza Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Posters

Final Conference Programme | Poster Session

Poster 101
‘P97c recombinant protein modulates the innate immune system through Toll-like receptor 5 (TLR5) activation and cytokine production’
Denis Archambault, Jessica Dion, Geneviève Bertheau-Mailhot, Claude Marchand and Steve Bourgault
(University of Quebec at Montreal, Montreal, Quebec, Canada)

Poster 102
‘Synthesis and potent adjuvant activity of Lipid A mimics bearing an aromatic scaffold’
Jordan D. Lewicky1, Genevieve M. Weir2, Rajkannan Rajagopalan2, Marc Mansour2, Leeladhar Sammatur2, Marianne M. Stanford2 and Zi-Hua Jiang1
(1 Department of Chemistry, Lakehead University, Thunder Bay, Ontario, Canada; 2 Immunovaccine, Halifax, Nova Scotia, Canada)

Poster 103
‘Increased immunogenicity and protective efficacy of the P. aeruginosa vaccine in mice using an alum and de-O-acylated lipooligosaccharide adjuvant system’
Ji In Ryu1, Seo Ri Wui1, Ara Ko1, Hien Thi Thu Do1, Yeon Jeong Lee1, Hark Jun Kim1, Shin Ae Park2, Kwang Sung Kim2, Yang Je Cho2 and Na Gyong Lee1
(1 Department of Bioscience and Biotechnology, Sejong University, Seoul, Republic of Korea; 2 R&D Center, EyeGene, Goyang, Republic of Korea)

Poster 104
‘Induction of fast and potent antibody responses in mice by MERS-CoV subunit vaccine adjuvanted with CIA06, a combination of alum and de-O-acylated lipooligosaccharide’
Yeon Jeong Lee, Seo Ri Wui, Ji In Ryu, Ara Ko, Hien Thi Thu Do, Hark Jun Kim and Na Gyong Lee
(Department of Bioscience and Biotechnology, Sejong University, Seoul, Republic of Korea)

Poster 105
‘Design and characterisation of a dissolving microneedle patch for transdermal vaccination with heat-Inactivated bacteria: A proof of concept study’
A.M. Rodgers1, M.T.C. McCrudden2, A.V. Dubois1, E.M Vicente-Perez2, R.J. Ingram1, R.F. Donnelly2 and A. Kissenpfennig1
(1 Centre for Experimental Medicine, Queen’s University Belfast, UK; 2 School of Pharmacy, Queen’s University Belfast, UK)

Poster 106
In ovo administration of innate immune stimulants\immuno-adjuvants and protection from early chick mortalities due to yolk sac infection’
Brenda Allan, Mishal Sarfraz, Wolfgang Köster, Colette Wheler and Arshud Dar
(Vaccine and Infectious Disease Organization-International Vaccine Centre, University Of Saskatchewan, Saskatoon, Canada)

Poster 107
‘Stabilising polio vaccines and their skin delivery using dissolvable microneedle patches’
Agnese Donadei1, Olga Ophorst2, Rimko Ten Have2, Heleen Kraan2, Olivia Flynn1, Ivo Ploemen2 and Anne Moore1
(1 School of Pharmacy, University College Cork, Cork, Ireland; 2 Institute of Translational Vaccinology (Intravacc), Bilthoven, Netherlands)

Poster 108
‘Investigating adjuvant potential of Astragaloside VII and its formulation with Astragalus polysaccharide for seasonal influenza vaccines’
Nilgün Yakubogullan1, Rükan Genç2, Serhan Cenk Özverel3, Fethiye Çöven4, Ay e Nalbantsoy3 and Erdal Bedir1
(1 Izmir Institute of Technology, Biotechnology and Bioengineering Department, Bioengineering Department, Gülbahçe, Urla, Izmir, Turkey; 2 Mersin University, Faculty of Engineering, Chemical Engineering Department, Mersin, Turkey; 3 Ege University, Faculty of Engineering, Bioengineering Department, Bornova, Izmir, Turkey; 4 Bornova Veterinary Control and Research Institute, Bornova, Izmir, Turkey)

Poster 109
‘Characterization of a modified coronaviral-like particle’
A. Naskalska, A. Dabrowska, A. Milewska, A. Wong, J. Kozie and K. Pyr
(Malopolskie Centrum Biotechnologii, Uniwersytet Jagiellonski, Krakow, Poland)

Poster 110
‘Novel RNA-based adjuvants with strong immunostimulatory activities improve the efficacy of VLP-based cancer vaccines’
Mahjoub Bihi1, Thorsten Klamp1, Mustafa Diken2,3, Sebastian Kreiter2,3 and Ugur Sahin1,2,3
(1 BioNTech Protein Therapeutics GmbH; 2 Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (Tron); 3 BioNTech RNA Pharmaceuticals GmbH, Mainz, Germany)

Poster 111
‘Characteristics of Montanide. ISA 51 VG adjuvant designed for therapeutic cancer vaccines’
Maria Lazaro, Aude Puget and Stephane Ascarateil
(SEPPIC, Paris La Defense, Puteaux, France)

Poster 112
‘Layer-by-layer coating of whole inactivated influenza virus (WIV): A single-shot vaccine approach?’
C. Lemoine1,2, M. Marti Favre1, V. Jakob1, W. Jiskoot3, N. Collin1, G. Borchard2 and C. Barnier-Quer1
(1 Vaccine Formulation Laboratory, University of Lausanne, Epalinges, Switzerland; 2 School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; 3 Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research, Leiden, The Netherlands)

Poster 113
‘Training in adjuvants and vaccine formulation’
M. Lawrenz1, C. Barnier-Quer2, L. Brunner2, P. Dubois1, G.Frank2, V. Jakob2, C. Lebas2, C. Lemoine2, M. Marti Favre2, R. Ventura2 and N. Collin2
(1 Vaccine Formulation Institute, Godalming, Surrey, UK; 2 Vaccine Formulation Laboratory, University of Lausanne, Epalinges, Switzerland)

 

MVADS 2017 Delegates

Login details will be supplied after you have registered for the event.


MVADS 2017 Sponsors

  • EVI
  • Mucosis
  • BPRC
  • NatureGeneTherapy.com
  • Janssen
  • Pfizer
  • Vaxart
  • IDRI
  • iZon Science
  • BioAster
  • Novavax
  • Precision Vaccines Program
  • CureVac
  • Matrivax
  • Seppic
  • National Institute of Allergy and Infectious Diseases
  • BIA Separations
  • Inovio
  • Univac
  • Sanofi Pasteur
  • Eurocine Vaccines
  • Brenntag
  • Mymetics
  • Aldevron
  • Bill and Melinda Gates Foundation
  • VisMederi
  • DNAvaccine.com

MVADS 2017 Downloads

MVADS 2017 Leaflet

MVADS 2017 Mailing List

Name
E-mail Address
What is 3+2-1?